Direct knockdown of phospho-PTM targets mediated by TRIM21 can improve personalized treatment in breast cancer.

The work demonstrated that TRIM-ing could directly reduce various oncogenic targets or their specific activated form inside the cancer cells without compensatory pathway activation, a conundrum limiting the therapeutic benefit of current personalized medicines.